Insider Transactions in Q3 2025 at Neurocrine Biosciences Inc (NBIX)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 07
2025
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
106,322
-17.12%
|
$13,396,572
$126.41 P/Share
|
|
Aug 07
2025
|
Kevin Charles Gorman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
106,322
+14.62%
|
$3,721,270
$35.99 P/Share
|
|
Aug 05
2025
|
Jude Onyia Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
3,116
-17.04%
|
-
|
|
Jul 10
2025
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
457
-8.81%
|
$61,695
$135.0 P/Share
|
|
Jul 10
2025
|
Ingrid Delaet Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
457
+8.1%
|
$36,103
$79.02 P/Share
|
|
Jul 09
2025
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
59,819
-76.59%
|
$7,776,470
$130.46 P/Share
|
|
Jul 09
2025
|
Jude Onyia Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
59,819
+43.37%
|
$5,024,796
$84.74 P/Share
|
|
Jul 02
2025
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,362
-52.68%
|
$2,647,060
$130.13 P/Share
|
|
Jul 02
2025
|
Jude Onyia Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,362
+34.5%
|
$1,710,408
$84.74 P/Share
|